From Preclinical Hype to Clinical Reality: The eIO Landscape at #AACR26

ONCrg's AACR team has been diving deep into the emerging IO landscape, and the shifts between preclinical and clinical data are telling a fascinating story.

#Oncology #ImmunoOncology #DrugDevelopment #OncologyInsights

Promotional banner with purple-blue microscopic cell background; white text reads “Meet our team at AACR 2026 in BOOTH #723” and the iRepertoire, Inc. logo appears in the lower-right.

The capabilities and services you need to gain greater insights into the patient immune response will be highlighted in booth #723 at AACR 2026!

Get a sneak peek of our immuno-oncology portfolio here:
irepertoire.com/immuno-oncol...

#AACR2026 #CancerResearch #ImmunoOncology #Immunotherapy

In this blog we demonstrate how #bioinformatics analysis is beneficial for the assessment of novel immuno-oncology therapies. Read it now!
www.fiosgenomics.com/using-bioinformatics-to-...
#oncology #immunooncology

Genetex Inc PD-L1 #recombinant #antibody has been validated for WB, ICC/IF, IHC-P and IHC-Fr & quality verified by knockdown, IFN-gamma induction & cross reactivity testing

🔗https://www.stratech.co.uk/products/GTX104763-GTX/

#immunooncology #immunohistochemistry #immunofluorescence #biotechnology

2nd International Conference on Cancer Research & Immuno-Oncology The conference provides an interactive environment where researchers, clinicians, and innovators can collaborate to accelerate progress in targeted

2nd International Conference on Cancer Research & Immuno-Oncology
April 3,4,5 2026
Atlantis the Royal, Palm Jumeirah - Crescent Road - Dubai

www.vydya.com/events/2nd-i...

#CancerResearch #ImmunoOncology #GenitourinaryCancer #GeneTherapy #PrecisionOncology
#OncologyConference #MedicalConference

In this blog we demonstrate how #bioinformatics analysis is beneficial for the assessment of novel immuno-oncology therapies. Read it now!
www.fiosgenomics.com/using-bioinformatics-to-...
#oncology #immunooncology

🚨 Call for Papers – Special Collection: Precision Immuno‑Oncology
We welcome original research, clinical trials, reviews, and real‑world evidence shaping precision cancer care.
Guest Editor: Dr. Peng Luo
🔗 Submission details: buff.ly/fqWNKby
#ImmunoOncology #PrecisionMedicine #Biomarkers

Stingray Therapeutics’ CEO Jon Northrup likens the immune system to Neo in the Matrix. Its checkpoint inhibitor, vizenpistat, complements the immune system’s fight against cancer. youtube.com/shorts/1PFjL...
#CancerResearch #TargetedTherapies #PrecisionMedicine #ImmunoOncology #LifeSciences

CEO Jon Northrup talks about the role of adaptive & innate immunity & how Stingray Therapeutics’ vizenpistat complements the immune system's fight against cancer.
youtube.com/shorts/64MLU...
#Biotechnology #CancerResearch #DrugDevelopment #ImmunoOncology #LifeSciences

We explore the complexities of Most Favored Nation pricing for pharmaceuticals with TuHURA CEO Dr James Bianco. Join in to hear how this might affect US and global commercialization efforts.
$HURA
#ImmunoOncology #CancerResearch #LifeSciences
youtu.be/GnVUVf7_2NE

Does TIGIT benefit no one…
Or does it benefit a biologically defined subset we failed to identify? 🤔

All-comers trials and conventional biomarkers ignore heterogeneous tumour immune contexts.

Is it time for true precision IO? 🔬

#ImmunoOncology #PrecisionMedicine #Biomarkers

TuHURA is running two clinical trials for IFx-2.0 in Merkel cell carcinoma. One is a Phase III and the other is a Phase II. Dr Bianco explains the difference.
$HURA #ImmunoOncology #CancerResearch #LifeSciences
youtu.be/iK0wkXlwLoQ

In this blog we demonstrate how #bioinformatics analysis is beneficial for the assessment of novel immuno-oncology therapies. Read it now!
www.fiosgenomics.com/using-bioinformatics-to-...
#oncology #immunooncology

Advance could expand immune therapy as a cancer treatment | Chemistry The development of antibody-lectin chimeras, which started in the lab of Stanford chemist Carolyn Bartozzi, shows promise in blocking the defenses put up by cancer cells and allowing the immune system...

Stanford’s Carolyn Bertozzi is leading a new cancer immunotherapy approach that helps the immune system see tumors by disrupting sugar-based camouflage - expanding who may benefit from treatment.

Learn more: chemistry.stanford.edu/news/advance...

#ImmunoOncology #BioorthogonalChemistry

TuHURA Biosciences CEO Dr. James Bianco explains the mechanism of action for the Delta Opioid Receptor which modifies the tumor microenvironment rather than targeting the tumor itself.
$HURA
#ImmunoOncology #CancerResearch #CancerImmunotherapy #ImmuneSuppression #MDSCs
youtu.be/8xSUa9LjsNk

HanchorBio teams with WuXi to produce immuno-oncology proteins The collaboration will focus on the advancement of HanchorBio’s oncology and autoimmune pipelines.

HanchorBio teams up with WuXi Biologics to accelerate the manufacturing of immuno-oncology fusion proteins. This partnership aims to streamline development timelines and advance innovative cancer therapies. #Biotech #ImmunoOncology

Read below:

www.bioprocessintl.com/deal-making/...

High-impact cancer research starts with the right samples.
IMMUcan opens access to trial-grade oncology biosamples from ~1,400 patients.
immucan.eu/how-to-colla...
#CancerResearch #ImmunoOncology #Biomarkers #MultiOmics

Scientists may have found key to treating hidden cancer growths Researchers say the findings offer a promising way to improve existing cancer therapies as well as develop new ones

Read about #CancerGrandChallenges Team #KOODAC’s innovative study, featured this week in @the-independent.com 👇
🔗 independent.co.uk/news/health/...

Funded through @cancergrand.bsky.social l by @cancerresearchuk.org , @institut-cancer.bsky.social & #Kika.

#CancerResearch #ImmunoOncology #MYC

TuHURA Biosciences acquired an anti-VISTA asset from Kineta last year. CEO Dr. James Bianco explains the role of the checkpoint inhibitor in leukemias such as AML.
$HURA
#AML #VISTA #ImmunoOncology
youtube.com/shorts/r5D79...

Overcoming immune evasion in solid tumours New findings from team KOODAC

Team #KOODAC ’s first @cellpress.bsky.social paper uncovers how MYC helps solid tumours evade immune detection—revealing a new model with major implications for immunotherapy.

Read the story behind the science
👇
Q&A: shorturl.at/7FXUw
Paper: shorturl.at/DYuWO

#CancerResearch #ImmunoOncology #MYC

Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies - PharmaTimes New manufacturing technologies aim to accelerate next-generation cell therapy development

#Cellistic #iPSCbasedplatforms #immunooncologytherapies #celltherapydevelopment #GMPmanufacturing #iPSCderivedcelltherapies #immunooncology #regenerativemedicine #EchoT #EchoCardio #EchoEndothelial #allogeneiccelltherapy #EchoNKsystem #celltherapy #autologousTcelltherapies #Tregs
zurl.co/EF2mP

𝗔𝗜-𝗽𝗼𝘄𝗲𝗿𝗲𝗱 𝗶𝗺𝗺𝘂𝗻𝗼𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝗮𝘀𝘀𝗲𝘀𝘀𝗺𝗲𝗻𝘁
Learn how AI analysis of effector cells captures dynamic interactions, activation, viability and killing efficiency to accelerate immunotherapy development: bit.ly/3Lz1WAt .
#ImmunoOncology #Medicine #Cancer

TuHURA Biosciences' CEO Dr. James Bianco explains how IFx-2.0 may work in other solid tumors besides Merkel cell carcinoma & show synergy with checkpoint inhibitors.
$HURA
#ImmunoOncology #CancerResearch #Oncology #BioTech #LifeSciences
youtube.com/shorts/62SOT...

TuHURA CEO Dr James Bianco explains how the delta opioid receptor (DOR) works and the way in which it affects immune system response
$HURA
#MDSCs #ImmunoOncology #CancerResearch #CancerTreatment #Oncology
youtube.com/shorts/eE8x8...

𝗪𝗵𝗮𝘁 𝗵𝗮𝗽𝗽𝗲𝗻𝘀 𝘄𝗵𝗲𝗻 𝗧 𝗰𝗲𝗹𝗹 𝗸𝗶𝗹𝗹𝗶𝗻𝗴 𝗵𝗶𝘁𝘀 𝗮 𝘄𝗮𝗹𝗹?
Dr Roddy O'Connor shares his work on metabolic engineering of #CART cells to improve their function in our on-demand webinar: bit.ly/4sYQ0ca
#Immunooncology

Dr Bianco introduces TuHURA’s Immune Modulating ADCs which link a VISTA inhibitor to a delta opioid receptor inhibitor to target the tumor microenvironment rather than the tumor itself
$HURA
#TumorMicroenvironment #ImmunoOncology #MDSCs #MyeloidCells #VISTA #Oncology #ADC youtube.com/shorts/jfTnJ...

🧬𝗛𝗼𝘄 𝘁𝗼 𝗲𝘃𝗮𝗹𝘂𝗮𝘁𝗲 𝘁𝗵𝗲 𝗰𝘆𝘁𝗼𝘁𝗼𝘅𝗶𝗰𝗶𝘁𝘆 𝗼𝗳 𝘆𝗼𝘂𝗿 𝗖𝗔𝗥-𝗧 𝗰𝗲𝗹𝗹 𝗮𝘂𝘁𝗼𝗺𝗮𝘁𝗶𝗰𝗮𝗹𝗹𝘆?
Learn more about Nanolive’s label-free solution for automated functional profiling of T cells and their targets in vitro: bit.ly/3LxebNY
#ImmunoOncology #LiveCellImaging #CART

Synapse: Your Connection to our MSK Authors
Meet: Jennifer Defazio
Research Focus: Medicine; Associate Attending

Immuno-oncologyDupilumab for bullous pemphigoid related to immune checkpoint inhibitors: A retrospective case series
synapse.mskcc.org/synapse/work...

#ImmunoOncology #Dupilumab

In this blog we demonstrate how #bioinformatics analysis is beneficial for the assessment of novel immuno-oncology therapies. Read it now!
www.fiosgenomics.com/using-bioinformatics-to-...
#oncology #immunooncology

Comprehensive cancer analysis reveals CFH as an immune-related and prognostic marker - PubMed This study implies the potential prognostic and immunological role of CFH in various cancers, and CFH could act as a biomarker for tumor immunotherapy.

Large-scale pan-cancer analysis identifies Complement Factor H (CFH) as a novel immune-related and prognostic biomarker, linking complement regulation to tumor immunity and patient outcomes. #CancerResearch #ImmunoOncology #Biomarkers #PrecisionMedicine buff.ly/XmlgOQB